Corbus Farmaceuticals Holdings (modificare)
Versiunea de la data 30 septembrie 2024 05:15
, 30 septembrie 2024The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei Corbus Farmaceuticals Holdings listata cu simbolul US.CRBP ==Descriere companie== Corbus Pharmaceuticals Holdings, Inc. (www.corbuspharma.com) is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. It develops a diverse pipeline of drug candidates across programs, including small molecules...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 2: | Linia 2: | ||
==Descriere companie== | ==Descriere companie== | ||
Corbus Pharmaceuticals Holdings, Inc. (www.corbuspharma.com) is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. It develops a diverse pipeline of drug candidates across programs, including small molecules as well as biologics. The Company's lead product candidate, Lenabasum, a novel, synthetic, oral, cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation, limit fibrosis and support tissue repair. Lenabasum is in clinical development for treatment of autoimmune diseases. It is evaluating lenabasum and is in a Phase III study in dermatomyositis, as well as a Phase II study in systemic lupus erythematosus (SLE). It designs cannabinoid receptor type 1 (CB1) inverse agonists to normalize metabolic abnormalities or limit inflammation and fibrosis. | [[CORBUS PHARMACEUTICALS HOLDINGS|Corbus Pharmaceuticals Holdings]], Inc. (www.corbuspharma.com) is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. It develops a diverse pipeline of drug candidates across programs, including small molecules as well as biologics. The Company's lead product candidate, Lenabasum, a novel, synthetic, oral, cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation, limit fibrosis and support tissue repair. Lenabasum is in clinical development for treatment of autoimmune diseases. It is evaluating lenabasum and is in a Phase III study in dermatomyositis, as well as a Phase II study in systemic lupus erythematosus (SLE). It designs cannabinoid receptor type 1 (CB1) inverse agonists to normalize metabolic abnormalities or limit inflammation and fibrosis. | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||